OSTEOARTHRITIS TREATMENT

Abstract

The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.

Description

[0001] This application is a Continuation of copending application Ser. No. 15/811,279, filed on Nov. 13, 2017, which is a Continuation of application Ser. No. 14/975,024, filed on Dec. 18, 2015, which is a Continuation of patented U.S. application Ser. No. 13/140,467 filed Aug. 4, 2011, which was patented as U.S. Pat. No. 9,243,061 on Jan. 26, 2016, which is the National Phase under 35 U.S.C. .sctn. 371 of International Application No. PCT/AU2009/001672, filed on Dec. 21, 2009, which claims the benefit under 35 U.S.C. .sctn. 119(e) to U.S. Provisional Application No. 61/139,679, filed Dec. 22, 2008, and U.S. Provisional Application No. 61/164,486, filed Mar. 30, 2009, all of which are incorporated by reference in their entireties.

FIELD OF THE INVENTION

[0002] The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.

BACKGROUND OF THE INVENTION

[0003] Osteoarthritis (OA), also known as degenerative arthritis, is a disease most prevalent in the old and obese. OA is a disease of the articular joints, but, unlike rheumatoid arthritis (RA), the disease is not systemic, usually affecting only one or a few joints. The disease leads to total destruction of the articular cartilage, sclerosis of the underlying bones, and osteophyte formation, resulting in loss of movement and pain. The ultimate result is often the need for a total joint replacement.

[0004] OA affects about .about.21 million people in the US, comprises 25% of all primary care physician visits, and accounts for 50% of all NSAID (non steroidal anti inflammatory drugs) prescriptions. There is currently no treatment available which slows or halts disease progression; today's drugs merely treat the symptoms. The incidence and severity of the disease increase with age. By the age of 65, 80% of Americans show radiographic evidence of OA though only 60% of them will be symptomatic. 65% of all joint disease by the age of 65 are OA. In 2006, there were 735,000 OA-related US hospitalizations.

[0005] Current OA drugs treat the symptoms of OA rather than the disease itself. Commonly used drugs in the treatment of OA include Non-steroidal anti-inflammatory drugs (NSAIDs), such as diacerin, voltaren. mobic and arthrotec (generic names: diclofenac, misoprostol, meloxicam). NSAIDs are mainly oral compounds which act by inhibiting prostaglandin synthesis in the central nervous system (CNS). Other commonly used drugs include non-narcotic analgesics, such as ultram (tramadol), COX-2 inhibitors, such as celebrax and arcoxia (celecoxib, etoricoxib), narcotic analgesiscs, such as duragesic (dextropropoxyphene fentanyl), hyaluraonic acids, such as suparts, hyalgan, orthovisc and synvisc (Hylan G-F20), and corticosteroids, such as predinisolone and methyl predinisolone. Present treatments for OA intend to obviate the need for surgery through tissue engineering, such as chondrocyte transplantation; however, these treatments are-only applicable for the treatment of last stage OA. Other approaches in the treatment of OA that are considered include prolotherapy, in which an irritant, such as dextrose, is injected into the affected joint, thereby causing an acute inflammatory reaction, but also strengthening and hopefully healing the tissues, ligaments, tendons, and cartilage. There is, thus, a high unmet medical need for the treatment of OA.

[0006] Some cytokines are known to be involved in osteoarthritis (Blom et al., Current Drug Targets (2008) 8:283). A few cytokines, such as IL-1, a `destructive` cytokine, and the anabolic growth factor transforming growth factor .beta. (TGF.quadrature. .beta.) are considered as potential drug targets.

[0007] Granulocyte macrophage colony-stimulating factor (GM-CSF) is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exit the circulation and migrate into tissue, whereupon they mature into macrophages. It is, thus, part of the natural immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of GM-CSF is found extracellularly as a homodimer. In particular, GM-CSF has been identified as an inflammatory mediator in autoimmune disorders, like rheumatoid arthritis (RA), leading to an increased production of pro-inflammatory cytokines, chemokines and proteases and, thereby, ultimately to articular destruction.

[0008] WO 06/0234412 discloses numerous biomarkers for osteoarthritis, which were identified by protein microarrays. One of the biomarkers identified is GM-CSF, for which a four-fold up-regulation is reported in OA tissue. However, no indication or suggestion is provided that GM-CSF may also be a point for therapeutic intervention, and a mere four-fold up-regulation in OA tissue, as identified with the technology disclosed in WO 06/0234412, also does not suggest the same. In a related vein, Devalaraja et al (US20020141994A1) cursorily mention OA among a long list of potentially suitable indications suitable for treatment with antagonists of colony stimulating factors. The list of indications includes atherosclerosis, sepsis, asthma, autoimmune disease, osteoporosis and rheumatoid arthritis. Besides other colony stimulating factors, such as M-CSF and G-CSF, GM-CSF is one of the colony stimulating factors mentioned in Devalaraja et al. Indeed, Devalaraja et al. include no data or other insights as to why antagonizing GM-CSF would be appropriate to treat a subject suffering from OA.

SUMMARY OF THE INVENTION

[0009] The present invention, for the first time, demonstrates that GM-CSF is a valid target for the treatment of OA. This finding is new, and the prior art does not teach, suggest or provide any rational for such a point of intervention in the treatment of OA. Accordingly, the invention provides, e.g., a method for the treatment of osteoarthritis in a subject, said method comprising the step of administering an effective amount of a GM-CSF antagonist to said subject.

[0010] In another aspect, the present invention contemplates a method for the prophylaxis of osteoarthritis in a subject, said method comprising the step of administering an effective amount of GM-CSF antagonist to said subject.

[0011] In another aspect, the present invention is directed to a composition comprising a GM-CSF antagonist capable of antagonizing the ability of GM-CSF from activating, proliferating, inducing growth and/or survival of cells in a subject suffering from osteoarthritis, or being suspected of suffering from osteoarthritis, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.

[0012] In another aspect, the present invention is directed to a composition comprising a GM-CSF antagonist useful in the treatment of osteoarthritis, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.

[0013] In particular aspects of the present invention, the GM-CSF antagonist is an antibody specific for GM-CSF.

[0014] In alternative aspects of the present invention, the GM-CSF antagonist is an antibody specific for the GM-CSF receptor.

[0015] In other aspects, the present invention is directed to the use of a GM-CSF antagonist in the preparation of a medicament in the treatment of osteoarthritis.

[0016] In other aspects, the present invention provides GM-CSF antagonists for the treatment of osteoarthritis.

[0017] Throughout this specification, unless the context requires otherwise, the words "comprise", "have" and "include" and their respective variations such as "comprises", "comprising", "has", "having", "includes" and "including" will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

BRIEF DESCRIPTION OF THE DRAWINGS

[0018] FIG. 1 shows quantitative data for joint damage in different regions assessed by histological scoring. The experimental set-up and the scoring system are described in Example 2. "Lat." stands for lateral, "Med." stands for medial. Statistical analysis was performed via Mann-Whitney. The data are statistically significant for Lat. Femur (p=0.02), Lat Tibia (p=0.003), Med, Tibia (p=0.001), and over all regions (Mean; p=0.002).

[0019] FIG. 2 shows exemplary histology sections of healthy control knees. Magnification is 100.times.. No cartilage damage, osteophyte formation, synovitis or deformations can be seen. S=synovial lining, C=cartilage layer.

[0020] FIG. 3 shows exemplary histology sections of the left knees of C57/BL6 mice in a model of collagenase-induced OA. Magnification is of the individual sections is indicated in the Figures. The top row of pictures shows that cartilage damage, osteophyte formation and synovitis are evident. O=osteophyte. S=synovial lining. The bottom row of pictures shows that joint deformation is also present.

[0021] FIG. 4 shows exemplary histology sections of the left knees of GM-CSF-/- mice in a model of collagenase-induced OA. Magnification is of the individual sections is indicated in the Figures. As can be seen, the abnormalities and/or damages are much less severe compared to the C57/BL6 mice (see FIG. 3) and are comparably to the healthy control mice (see FIG. 2). O=osteophyte. S=synovial lining.

[0022] FIG. 5 shows the knee joint histology scoring of the therapeutic treatment with a

[0023] GM-CSF antibody in a mouse model of OA. Lat.=Lateral. Med.=Medial. Results are expressed as mean.+-.SEM. As can be seen mice treated with anti-GM-CSF antibody show less disease.

[0024] FIG. 6 shows the result of an experiment assessing the hind limb weight distribution in an incapacitance meter. Data are significant (unpaired t-test) from day 27 post OA induction onwards, as indicated in the graph.

DETAILED DESCRIPTION OF THE INVENTION

[0025] The present invention demonstrates that GM-CSF is a valid target for the treatment of OA. In this respect, the invention provides, in one aspect, methods of using a GM-CSF antagonist to bring about a prophylactic or therapeutic benefit in the field of OA.

[0026] The present invention provides therapeutic methods comprising the administration of a therapeutically effective amount of a GM-CSF antagonist to a subject in need of such treatment. A "therapeutically effective amount" or "effective amount", as used herein, refers to the amount of a GM-CSF antagonist necessary to elicit the desired biological response. In accordance with the subject invention, the therapeutic effective amount is the amount of a GM-CSF antagonist necessary to treat and/or prevent osteoarthritis.

[0027] "GM-CSF antagonists", as used herein, includes GM-CSF antagonists in its broadest sense; any molecule which inhibits the activity or function of GM-CSF, or which by any other way exerts a therapeutic effect on GM-CSF is included. The term GM-CSF antagonists includes, but is not limited to, antibodies specifically binding to GM-CSF, inhibitory nucleic acids specific for GM-CSF or small organic molecules specific for GM-CSF. Also within the meaning of the term GM-CSF antagonist are antibodies specifically binding to the GM-CSF receptor, inhibitory nucleic acids specific for the GM-CSF receptor or small organic molecules specific for the GM-CSF receptor.

[0028] Inhibitory nucleic acids include, but are not limited to, antisense DNA, triplex-forming oligonucleotides, external guide sequences, siRNA and microRNA. Useful inhibitory nucleic acids include those that reduce the expression of RNA encoding GM-CSF by at least 20, 30, 40, 50, 60, 70, 80, 90 or 95 percent compared to controls. Inhibitory nucleic acids and methods of producing them are well known in the art. siRNA design software is available.

[0029] Small organic molecules (SMOLs) specific for GM-CSF or the GM-CSF receptor may be identified via natural product screening or screening of chemical libraries. Typically the molecular weight of SMOLs is below 500 Dalton, more typically from 160 to 480 Daltons. Other typical properties of SMOLs are one or more of the following:

[0030] The partition coefficient log P is in the range from -0.4 to +5.6

[0031] The molar refractivity is from 40 to 130

[0032] The number of atoms is from 20 to 70

[0033] For reviews see Ghose et al, J Combin Chem: 1:55-68, 1999 and Lipinski et al, Adv Drug Del Rev 23:3-25, 1997.

[0034] Preferably, a GM-CSF antagonist for use in the present invention is an antibody specific for GM-CSF or specific for the GM-CSF receptor. Such an antibody may be of any type, such as a murine, a rat, a chimeric, a humanized or a human antibody. A "human" antibody or functional human antibody fragment is hereby defined as one that is not chimeric (e.g., not "humanized") and not from (either in whole or in part) a non-human species. A human antibody or functional antibody fragment can be derived from a human or can be a synthetic human antibody. A "synthetic human antibody" is defined herein as an antibody having a sequence derived, in whole or in part, in silico from synthetic sequences that are based on the analysis of known human antibody sequences. In silico design of a human antibody sequence or fragment thereof can be achieved, for example, by analyzing a database of human antibody or antibody fragment sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Another example of a human antibody or functional antibody fragment is one that is encoded by a nucleic acid isolated from a library of antibody sequences of human origin (i.e., such library being based on antibodies taken from a human natural source).

[0035] A "humanized antibody" or functional humanized antibody fragment is defined herein as one that is (i) derived from a non-human source (e.g., a transgenic mouse which bears a heterologous immune system), which antibody is based on a human germline sequence; or (ii) chimeric, wherein the variable domain is derived from a non-human origin and the constant domain is derived from a human origin or (iii) CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frameworks of the variable domain are of human origin and the constant domain (if any) is of human origin.

[0036] The term "chimeric antibody" or functional chimeric antibody fragment is defined herein as an antibody molecule which has constant antibody regions derived from, or corresponding to, sequences found in one species and variable antibody regions derived from another species. Preferably, the constant antibody regions are derived from, or corresponding to, sequences found in humans, e.g. in the human germ line or somatic cells, and the variable antibody regions (e.g. VH , VL , CDR or FR regions) are derived from sequences found in a non-human animal, e.g. a mouse, rat, rabbit or hamster.

[0037] As used herein, an antibody "binds specifically to", "specifically binds to", is "specific to/for" or "specifically recognizes" an antigen (here, GM-CSF or, alternatively, the GM-CSF receptor) if such antibody is able to discriminate between such antigen and one or more reference antigen(s), since binding specificity is not an absolute, but a relative property. The reference antigen(s) may be one or more closely related antigen(s), which are used as reference points, e.g. IL3, IL5, IL-4, IL13 or M-CSF. In its most general form (and when no defined reference is mentioned), "specific binding" is referring to the ability of the antibody to discriminate between the antigen of interest and an unrelated antigen, as determined, for example, in accordance with one of the following methods. Such methods comprise, but are not limited to Western blots, ELISA-, RIA-,ECL-, IRMA-tests and peptide scans. For example, a standard ELISA assay can be carried out. The scoring may be carried out by standard color development (e.g. secondary antibody with horseradish peroxide and tetramethyl benzidine with hydrogenperoxide). The reaction in certain wells is scored by the optical density, for example, at 450 nm. Typical background (=negative reaction) may be 0.1 OD; typical positive reaction may be 1 OD. This means the difference positive/negative can be more than 10-fold. Typically, determination of binding specificity is performed by using not a single reference antigen, but a set of about three to five unrelated antigens, such as milk powder, BSA, transferrin or the like. Additionally, "specific binding" may relate to the ability of an antibody to discriminate between different parts of its target antigen, e.g. different domains or regions of GM-CSF or the GM-CSF receptor, or between one or more key amino acid residues or stretches of amino acid residues of GM-CSF or the GM-CSF receptor.

[0038] Also, as used herein, an "immunoglobulin" (Ig) hereby is defined as a protein belonging to the class IgG, IgM, IgE, IgA, or IgD (or any subclass thereof), and includes all conventionally known antibodies and functional fragments thereof. A "functional fragment" of an antibody/immunoglobulin hereby is defined as a fragment of an antibody/immunoglobulin (e.g., a variable region of an IgG) that retains the antigen-binding region. An "antigen-binding region" of an antibody typically is found in one or more hypervariable region(s) of an antibody, i.e., the CDR-1, -2, and/or -3 regions; however, the variable "framework" regions can also play an important role in antigen binding, such as by providing a scaffold for the CDRs. Preferably, the "antigen-binding region" comprises at least amino acid residues 4 to 103 of the variable light (VL) chain and 5 to 109 of the variable heavy (VH) chain, more preferably amino acid residues 3 to 107 of VL and 4 to 111 of VH, and particularly preferred are the complete VL and VH chains (amino acid positions 1 to 109 of VL and 1 to 113 of VH; numbering according to WO 97/08320). A preferred class of immunoglobulins for use in the present invention is IgG. "Functional fragments" of the invention include the domain of a F(ab').sub.2 fragment, a Fab fragment, scFv or constructs comprising single immunoglobulin variable domains or single domain antibody polypeptides, e.g. single heavy chain variable domains or single light chain variable domains. The F(ab').sub.2 or Fab may be engineered to minimize or completely remove the intermolecular disulphide interactions that occur between the C.sub.H1 and C.sub.L domains.

[0039] An antibody of the invention may be derived from a recombinant antibody library that is based on amino acid sequences that have been designed in silico and encoded by nucleic acids that are synthetically created. In silico design of an antibody sequence is achieved, for example, by analyzing a database of human sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Methods for designing and obtaining in silico-created sequences are described, for example, in Knappik et al, J. Mol. Biol. 296:57, 2000; Krebs et al, J. Immunol. Methods. 254:67, 2001; Rothe et al, J. Mol. Biol. 376:1182, 2008 and U.S. Pat. No. 6,300,064 issued to Knappik et al 2000 supra, which hereby are incorporated by reference in their entirety.

[0040] Any antibody specific for GM-CSF may be used with the present invention. Exemplary antibodies are disclosed in U.S. Pat. No. 11/914,599, which is incorporated by reference in its entirety. Other exemplary antibodies include antibodies comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:1 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2. Yet other exemplary antibodies include antibodies which are derived from antibodies comprising a heavy chain variable region as depicted in SEQ ID NO:1 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2. Yet other exemplary antibodies include antibodies which have the same specificity and/or bind to the same epitope as antibodies comprising a heavy chain variable region as depicted in SEQ ID NO:1 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2. Yet other exemplary antibodies include antibodies which comprise a heavy chain variable region which is at least 70%, at least 80%, at least 90% or at least 95% homologous to the sequence depicted in SEQ ID NO:1. Yet other exemplary antibodies include antibodies which comprise a light chain variable region which is at least 70%, at least 80% , at least 90% or at least 95% homologous to the sequence depicted in SEQ ID NO:2.

TABLE-US-00001 SEQ ID NO: 1: Met Glu Leu Ile Met Leu Phe Leu Leu Ser Gly Thr Ala Gly Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Asn Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Asp Trp Ile Gly Tyr Ile Ala Pro Tyr Ser Gly Gly Thr Gly Tyr Asn Gln Glu Phe Lys Asn Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys Ala Arg Arg Asp Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Arg Val Ser Ser Val Ser Gly Ser SEQ ID NO: 2: Met Gly Phe Lys Met Glu Ser Gln Ile Gln Val Phe Val Tyr Met Leu Leu Trp Leu Ser Gly Val Asp Gly Asp Ile Val Met Ile Gln Ser Gln Lys Phe Val Ser Thr Ser Val Gly Asp Arg Val Asn Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Ser Asn Val Ala Trp Leu Gln Gln Lys Pro Gly Gln Ser Pro Lys Thr Leu Ile Tyr Ser Ala Ser Tyr Arg Ser Gly Arg Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Ile Leu Thr Ile Thr Thr Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Phe Asn Arg Ser Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Lys Gly Glu Phe

[0041] Alternative exemplary antibodies that can be used in the present invention are antibodies comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:3 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:4. Other exemplary antibodies include antibodies which are derived from antibodies comprising a heavy chain variable region as depicted in SEQ ID NO:3 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:4. Yet other exemplary antibodies include antibodies which have the same specificity and/or bind to the same epitope as antibodies comprising a heavy chain variable region as depicted in SEQ ID NO:3 or an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:4. Yet other exemplary antibodies include antibodies which comprise a heavy chain variable region which is at least 70%, at least 80%, at least 90 or at least 95% homologous to the sequence depicted in SEQ ID NO:3. Yet other exemplary antibodies include antibodies which comprise a light chain variable region which is at least 70%, at least 80%, at least 90% or at least 95% homologous to the sequence depicted in SEQ ID NO:4.

TABLE-US-00002 SEQ ID NO. 3: heavy MOR QVQLVESGGGLVQPGGSLRLSCAASGFTESSYWMNWVRQAPGKGLEWVSGI ENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGF GTDFWGQGTLVTVSS SEQ ID NO. 4: light MOR DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKR PSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLT VLGQ

[0042] Alternative exemplary antibodies that can be used in the present invention are antibodies comprising a H-CDR3 sequence selected from:

TABLE-US-00003 (SEQ ID NO. 5) Ser Gly Leu Ile Phe Asp Tyr Trp Leu Asp, 1 5 10 (SEQ ID NO: 6) Ser Gly Leu Ile Ile Asp Ala Leu Ser Pro, 1 5 10 (SEQ ID NO: 7) Thr Ser Leu Met Ser Ile Tyr Phe Asp Tyr, 1 5 10 (SEQ ID NO: 8) Ser Gly Leu Leu Phe Leu Tyr Phe Asp Tyr, 1 5 10 (SEQ ID NO: 9) Ser Gly Leu Ile Asn Leu Gly Met His Pro, 1 5 10 (SEQ ID NO: 10) Ser Gly Leu Ile Phe Asp Ala Leu Arg Asp, 1 5 10 (SEQ ID NO: 11) Ser Gly Leu Ile Phe Asp Lys Leu Thr Ser, 1 5 10 (SEQ ID NO: 12) Ser Gly Leu Ile Asn Leu His Phe Asp Thr, 1 5 10 (SEQ ID NO: 13) Ser Thr His Phe Ser Ala Tyr Phe Asp Tyr, 1 5 10 (SEQ ID NO: 14) Ser Gly Leu Ile Net Asp Lys Leu Asp Asn, 1 5 10 (SEQ ID NO: 15) Ser Gly Leu Ile Ile Asp Asn Leu Asn Pro, 1 5 10 and (SEQ ID NO: 16) Ser Gly Leu Ile Ala Val Tyr Phe Asp Tyr. 1 5 10

[0043] Preferably, the antibodies comprising a H-CDR3 sequence selected from any one of SEQ ID NOs. 5-16, additionally comprise the following H-CDR1 sequence:

TABLE-US-00004 (SEQ ID NO: 17) Asp Tyr Leu Leu His, 1 5

and/or the following H-CDR2 sequence:

TABLE-US-00005 (SEQ ID NO:18) Trp Leu Asn Pro Tyr Ser Gly Asp Thr Asn Tyr Ala Gln 1 5 10 Lys Gly Phe Gln, 15

and/or the following L-CDR1 sequence:

TABLE-US-00006 (SEQ ID NO: 19) Arg Ala Ser Gln Asn Ile Arg Asn Ile Leu Asn, 1 5 10

and/or the following L-CDR2 sequence:

TABLE-US-00007 (SEQ ID NO: 20) Ala Ala Ser Asn Leu Gln Ser, 1 5

and/or the following L-CDR3 sequence:

TABLE-US-00008 (SEQ ID NO: 21) Gln Gln Ser Tyr Ser Met Pro Arg Thr. 1 5

[0044] Alternative exemplary antibodies that can be used in the present invention are antibodies comprising the following L-CDR1 sequence:

TABLE-US-00009 (SEQ ID NO: 22) Arg Ala Ser His Arg Val Ser Ser Asn Tyr Leu Ala, 1 5 10

and/or the following L-CDR2 sequence:

TABLE-US-00010 (SEQ ID NO: 23) Gly Ala Ser Asn Arg Ala Thr, 1 5

and/or the following L-CDR3 sequence:

TABLE-US-00011 (SEQ ID NO: 24) Gln Gln Tyr Ala Ser Ser Pro Val Thr, 1 5

and/or the following H-CDR1 sequence:

TABLE-US-00012 (SEQ ID NO: 25) Gly Tyr Ile Phe Pro Thr Phe Ala Leu His, 1 5 10

and/or the following H-CDR2 sequence:

TABLE-US-00013 (SEQ ID NO: 26) Ser Ile Asn Thr Ala Ser Gly Lys Thr Lys Phe Ser Thr 1 5 10 Lys Phe Gln, 15

and/or the following H-CDR3 sequence:

TABLE-US-00014 (SEQ ID NO: 27) Asp Arg Phe Gln Asn Ile Met Ala Thr Ile Leu Asp 1 5 10 Val.

[0045] Preferably said antibody comprise all the CRDs of SEQ ID NOs. 22-27.

[0046] The GM-CSF receptor is a member of the haematopoietin receptor superfamily. It is heterodimeric, consisting of an alpha and a beta subunit. The alpha subunit is highly specific for GM-CSF whereas the beta subunit is shared with other cytokine receptors, including IL3 and IL5. This is reflected in a broader tissue distribution of the beta receptor subunit. The alpha subunit, GM-CSFR .alpha., is primarily expressed on myeloid cells and non-haematopoetic cells, such as neutrophils, macrophages, eosinophils, dendritic cells, endothelial cells and respiratory epithelial cells. Full length GM-CSFR .alpha. is a 400 amino acid type I membrane glycoprotein that belongs to the type I cytokine receptor family, and consists of a 22 amino acid signal peptide (positions 1-22), a 298 amino acid extracellular domain (positions 23-320), a transmembrane domain from positions 321-345 and a short 55 amino acid intra-cellular domain. The signal peptide is cleaved to provide the mature form of GM-CSFR .alpha. as a 378 amino acid protein. cDNA clones of the human and murine GM-CSFR .alpha. are available and, at the protein level, the receptor subunits have 36% identity. GM-CSF is able to bind with relatively low affinity to the a subunit alone (Kd 1-5 nM) but not at all to the .beta. subunit alone. However, the presence of both a and .beta. subunits results in a high affinity ligand-receptor complex (Kd 100 pM). GM-CSF signalling occurs through its initial binding to the GM-CSFR .alpha. chain and then cross-linking with a larger subunit the common .beta. chain to generate the high affinity interaction, which phosphorylates the JAK-STAT pathway.

[0047] Any antibody specific for GM-CSF receptor may be used with the present invention. Exemplary antibodies include antibodies comprising an amino acid sequence of a H-CDR3 sequence depicted in any one of SEQ ID No's.:28-46. Other exemplary antibodies include antibodies which are derived from antibodies comprising an amino acid sequence of a H-CDR3 sequence depicted in any one of SEQ ID No's.:28-46. Yet other exemplary antibodies include antibodies which have the same specificity and/or bind to the same epitope as antibodies comprising an amino acid sequence of a H-CDR3 sequence depicted in any one of SEQ ID No's.:28-46. Yet other exemplary antibodies include antibodies which comprise a H-CDR3 sequence which is at least 70%, at least 80%, at least 90% or at least 95% homologous to the H-CDR3 sequence depicted in any one of SEQ ID No's.:28-46.

TABLE-US-00015 SEQ ID No: 28: Val Gly Ser Phe Ser Gly Ile Ala Tyr Arg Pro 5 10 SEQ ID No: 29: Val Gly Ser Phe Ser Gly Pro Ala Leu Arg Pro 5 10 SEQ ID No: 30: Val Gly Ser Phe Ser Pro Pro Thr Tyr Gly Tyr 5 10 SEQ ID No: 31: Val Gly Ser Phe Ser Gly Tyr Pro Tyr Arg Pro 5 10 SEQ ID No: 32: Val Gly Ser Phe Ser Pro Leu Thr Leu Gly Leu 5 10 SEQ ID No: 33: Val Gly Ser Phe Ser Gly Pro Val Tyr Gly Leu 5 10 SEQ ID No: 34: Val Gly Ser Phe Ser Pro Pro Ala Tyr Arg Pro 5 10 SEQ ID No: 35: Val Gly Ser Phe Ser Pro Val Thr Tyr Gly Leu 5 10 SEQ ID No: 36: Val Gly Ser Phe Ser Gly Leu Ala Tyr Arg Pro 5 10 SEQ ID No: 37: Val Gly Ser Phe Ser Pro Ile Thr Tyr Gly Leu 5 10 SEQ ID No: 38: Val Gly Ser Phe Ser Gly Trp Ala Phe Asp Tyr 5 10 SEQ ID No: 39: Val Gly Ser Phe Ser Gly Trp Ala Phe Asp Tyr 5 10 SEQ ID No: 40: Leu Gly Ser Val Thr Ala Trp Ala Phe Asp Tyr 5 10 SEQ ID No: 41: Ala Gly Ser Ile Pro Gly Trp Ala Phe Asp Tyr 5 10 SEQ ID No: 42: Val Gly Ser Phe Ser Pro Leu Thr Met Gly Leu 5 10 SEQ ID No: 43: Val Gly Ser Phe Ser Pro Leu Thr Met Gly Leu 5 10 SEQ ID No: 44: Val Gly Ser Phe Ser Gly Pro Ala Leu His Leu 5 10 SEQ ID No: 45: Val Gly Ser Val Ser Arg Ile Thr Tyr Gly Phe 5 10 SEQ ID No: 46: Val Gly Ser Phe Ser Pro Leu Thr Leu Gly Leu 5 10

[0048] In certain aspects, the present invention provides methods for the treatment of osteoarthritis in a subject, said method comprising the step of administering a GM-CSF antagonist to said subject. "Subject", as used in this context refers to any mammal, including rodents, such as mouse or rat, and primates, such as cynomolgus monkey (Macaca fascicularis), rhesus monkey (Macaca mulatta) or humans (Homo sapienss). Preferably the subject is a primate, most preferably a human.

[0049] In certain aspect, the present invention provides a composition comprising a GM-CSF antagonist capable of antagonizing the ability of GM-CSF from activating, proliferating, inducing growth and/or survival of cells in a subject suffering from osteoarthritis, or being suspected of suffering from osteoarthritis, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents. Anti-GM-CSF antibodies of the present invention may antagonize any of the roles of GM-CSF in osteoarthritis.

[0050] In another aspect, the present invention provides a method for the prophylaxis of osteoarthritis in a subject, said method comprising administering a GM-CSF antagonist to said subject. "Prophylaxis" as used in this context refers to methods which aim to prevent the onset of a disease or which delay the onset of a disease.

[0051] In certain aspects, the present invention provides a composition comprising a GM-CSF antagonist useful in the treatment of osteoarthritis, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.

[0052] In other aspects, the present invention provides the use of a GM-CSF antagonist in the preparation of a medicament in the treatment of osteoarthritis.

[0053] In other aspects, the present invention provides GM-CSF antagonists for the treatment of osteoarthritis.

[0054] The compositions of the present invention are preferably pharmaceutical compositions comprising a GM-CSF antagonist and a pharmaceutically acceptable carrier, diluent or excipient, for the treatment of osteoarthritis. Such carriers, diluents and excipients are well known in the art, and the skilled artisan will find a formulation and a route of administration best suited to treat a subject with the GM-CSF antagonists of the present invention.

[0055] In another aspect the present invention provides a genetically engineered mammal having a GM-CSF -/- genotype. In particular aspects said mammal is a mouse. The terms "knock-out" mouse (or mammal), a mouse (or mammal) "disrupted in" a certain gene, and a mouse (or mammal) with a "-/- genotype" are used interchangeably in the present invention and are art recognized. Respective animals are deficient in a respective gene, here GM-CSF, on both alleles of the chromosome.

Example 1

Generation of a GM-CSF-/- Mouse

[0056] The generation of GM-CSF-/- mice is described in Stanley et al (1994). Proc. Natl. Acad. Sci. USA 91:5592. Briefly, chimeric mice were generated by microinjection of 129/OLA-derived ES cells (H-2b) with a disrupted GM-CSF gene into C57BL/6 (H-2b) host blastocysts. Germline transmitters of the mutated GM-CSF allele were crossed with C57BL/6 mice for 11 generations, giving GM-CSF+/- mice that were interbred to yield the GM-CSF-/-, GM-CSF+/-, and GM-CSF+/+ mice used for the experiments. GM-CSF genotype status was determined by PCR analysis of tail DNA. Animals were fed standard rodent chow and water ad libitum and were housed with same sex littermates in sawdust-lined cages. Mice of both sexes were consigned to experiments at 8 to 15 wk of age

Example 2

Validation of GM-CSF as a Target for Osteoarthritis

[0057] GM-CSF-/- mice were compared to C57/BL6 mice (see e.g. Mills et al, J Immunol 164:6166-6173, 2000) in an experimental model of osteoarthritis.

[0058] Method: Mice (n=10 per group) received an intra-articular injection of collagenase in the leftknee on day -2 and day 0 (Blom et al, Arthritis Rheum 56:147-157, 2007). At day 42 the mice were killed, the knee joints collected, fixed, de-calcified, embedded in paraffin and cut at 7 .mu.m with a microtome. Slides were then stained with Safranin-O/Fast Green and Haematoxylin and Eosin to demonstrate joint pathology. Pathology investigated includes: cartilage damage, synovitis, osteophyte formation and joint deformation.

[0059] The scoring system used for cartilage pathology was as follows:

TABLE-US-00016 Grade 0 Normal 1 Irregular but intact 1.5 Irregular with rough surface 2 Superficial fibrillation 2.5 Superficial fibrillation with reduced cells in cartilage layer 3 Vertical fissures 3.5 Branching and/or horizontal fissures, tidemark ruptures 4 Cartilage loss not extending to the tide mark 4.5 Cartilage loss extending to the tide mark 5 Cartilage loss beyond the tide mark but not extending to the bone 5.5 Cartilage loss extending to the bone 6 Bone loss/remodeling/deformation Stage 1 <10% area damaged 2 10-25% area damaged 3 25-50% area damaged 4 50-75% area damaged

[0060] The grade was multiplied by the stage to give the score.

[0061] This scoring system is based on a recognized method to assess OA histopathology in clinical and experimental OA. See Pritzker et al, Osteoarthritis Cartilage 14:13-29, 2006. Grade is defined as OA depth progression into cartilage. Stage is defined as the horizontal extent of cartilage involvement, i.e. how much of the cartilage is affected. Grade is multiplied by the stage to give the score to give an overall score, so as to represent a combined assessment of OA severity and extent. Up to six sections are scored per mouse.

[0062] Results: Inspection of these joints showed that the GM-CSF-/- mice show less knee joint pathology than the control mice, indicating the role of GM-CSF in normal osteoarthritis pathology and progression. Pathology observed in the C57/Bl6 mice includes severe damage to the cartilage layer, osteophyte formation, joint deformation and synovitis. The GM-CSF-/- mice showed no osteophyte formation or joint deformation and much less cartilage damage and synovitis.

[0063] Quantitatve data on--joint damage in different regions are shown in FIG. 1. Representative histology is shown in FIGS. 2 (healthy control knees), 3 (C57/BL6 left knees) and 4 (GM-CSF-/- left knees). GM-CSF gene-deficient mice developed less collagenase-induced OA pathology, compared to C57BL/6 mice.

[0064] In summary, GM-CSF-/- mice showed strongly decreased knee joint pathology compared to C57/BL6 mice in an experimental model of osteoarthritis and validated GM-CSF as a drug target for therapeutic intervention for osteoarthritis.

Example 3

Therapeutic Effectiveness of GM-CSF Antagonists in the Treatment of OA

[0065] In this experiment we used a monoclonal antibody specific for GM-CSF to demonstrate that a GM-CSF antagonist can be effective to treat osteoarthritis.

Collagen-Induced OA Mouse Model:

[0066] C57BL/6 mice were given 1 unit of collagenase type VII intra-articularly into the right knee on days 0 and 2 to induce joint instability (see Blom et al. (2004) Osteoarthritis Cartilage.12; 627-35).

Anti-GM-CSF antibody treatment:

[0067] 20 mice were randomly divided into 2 groups (10 mice/group).

[0068] Group 1 (n=10): anti-GM-CSF antibody (22E9)

[0069] Group 2 (n=10): IgG2a isotype control antibody.

[0070] Mice were treated intraperitoneally, three times per week for 6 weeks with 250 .mu.g/mouse/treatment anti-GM-CSF antibody (22E9) or IgG2a isoptype control antibody. Treatment started 4 days before the induction of OA (prophylactic), i.e. mice were treated on day -4, day -2, day 0 (the day of the first collagenase injection), then 3 times per week until the end of the experiment at 6 weeks). At weeks 2, 4 and 6, mice were bled. Serum will be checked for antibody content and immunogenicity against 22E9. Both, the control antibody and the anti-GM-CSF antibody were purified to contain less than 10 Endotoxin Units/ml.

[0071] The antibody 22E9 was used as an exemplary anti-GM-CSF antibody. 22E9, which is of IgG2a isotype, is a rat anti-mouse GM-CSF-specific antibody. 22E9 was purchased from AbD Serotec (Martinsried, Germany; Cat.No. 1023501). Alternative suppliers exist, e.g. eBioscience (SanDiego, Calif., USA, Cat. No. 14-7331).

Histology:

[0072] 6-weeks post final injections, histology was performed on the mice knee joints. The knee joints were collected, fixed, de-calcified, embedded in paraffin and cut at 7 .mu.m with a microtome. Slides were stained with Safranin-O/Fast Green and Haematoxylin and Eosin to demonstrate joint pathology. Pathology investigated included: cartilage damage, synovitis, osteophyte formation and joint deformation.

[0073] The same scoring system as in Example 2 was used for cartilage pathology. Grade was multiplied by the stage to give the score.

[0074] The following scoring system was used for synovitis (Synovial layer scoring system):

TABLE-US-00017 0 No changes compared to normal joints 1 Thickening of the synovial lining and some influx of inflammatory cells 2 Thickening of the synovial lining and intermediate influx of inflammatory cells 3 Profound thickening of the synovial lining and maximal observed influx of inflammatory cells

Pain Measurements:

[0075] An indicator of pain used for OA models is differential distribution of weight measured using an Incapacitance Meter. This instrument measures changes in weight distribution between the operated and contralateral, unoperated hind limb. Mice were allowed to acclimatize to the equipment on three occasions prior to the experiment. Weight placed on each hind limb was measured over a 5 second period. Three separate measurements taken per mouse for each time point then averaged. Measurements were performed 2 times per week throughout the experiment. Results are expressed as collagenase injected limb/control limb.times.100.

Results:

[0076] For all areas analyzed in histology (except the Medial Femur), i.e. the Lateral Femur, the Lateral Tibia, and the Medial Tibia, there was a clear trend towards less disease in mice treated with anti-GM-CSF antibody. Results are depicted in FIG. 5.

[0077] Assessment of the weight distribution, as a measure of pain associated with the arthritis, showed a significant shift in weight away from the arthritic knee from day 27 onwards in the anti-GM-CSF mAb-treated group compared to the control mAb-treated group. Results are depicted in FIG. 6.

[0078] Mice treated with a GM-CSF antagonist showed less disease as compared to mice treated with the control antibody. Mice treated with the GM-CSF antagonist also showed significantly less pain in the latter stages of disease compared to mice treated with the control antibody. Mice treated with the isotype control antibody showed significant increased signs of osteoarthritis as compared to the mice which received the GM-CSF-specific antibody. This demonstrates that GM-CSF antagonists are effective in the treatment of OA.

Example 4

Therapeutic Effectiveness of a GM-CSF Specific Antibody Comprising SEQ ID NOs. 1 or 2

[0079] Example 3 is repeated, whereby as GM-CSF antagonist, a GM-CSF specific antibody comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:1 or comprising an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2 is used. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0080] The animals treated with the isotype control antibody shows significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF specific antibody comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:1 or comprising an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:2. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 5

Therapeutic Effectiveness of a GM-CSF Specific Antibody Comprising SEQ ID NOs. 3 or 4

[0081] Example 3 is repeated. As GM-CSF antagonist, a GM-CSF specific antibody comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:3 or comprising an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:4 is used. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0082] The animals, e.g. rat, treated with the isotype control antibody show significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF specific antibody comprising an amino acid sequence of a heavy chain variable region as depicted in SEQ ID NO:3 or comprising an amino acid sequence of a light chain variable region as depicted in SEQ ID NO:4. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 6

Therapeutic Effectiveness of a GM-CSF Specific Antibodies Comprising SEQ ID NOs. 5-20

[0083] Example 3 is repeated. As GM-CSF antagonist, a GM-CSF specific antibody comprising a H-CDR3 sequence selected from any one of SEQ ID NOs. 5-16 is used. Preferably, said antibodies additionally comprise the H-CDR1 sequence of SEQ ID NO:16, and/or the H-CDR2 sequence of SEQ ID NO:17, and/or the L-CDR1 sequence of SEQ ID NO:18, and/or the L-CDR2 sequence of SEQ ID NO:19), and/or the L-CDR3 sequence of SEQ ID NO:20. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0084] The animals, e.g. rat, treated with the isotype control antibody show significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF specific antibody according to the present example. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 7

Therapeutic Effectiveness of a GM-CSF Specific Antibodies Comprising SEQ ID NOs. 21-26

[0085] Example 3 is repeated. As GM-CSF antagonist, a GM-CSF specific antibody comprising the L-CDR1 sequence of SEQ ID NO:22, and/or the L-CDR2 sequence of SEQ ID NO:23, and/or the L-CDR3 sequence of SEQ ID NO:24, and/or the H-CDR1 sequence of SEQ ID NO:25, and/or the H-CDR2 sequence of SEQ ID NO:26, and/or the H-CDR3 sequence of SEQ ID NO:27 is used. Preferably said antibody comprise all the CRDs of SEQ ID NOs. 22-27. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0086] The animals, e.g. rat, treated with the isotype control antibody show significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF specific antibody according to the present example. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 8

Therapeutic Effectiveness of Antibodies Specific for the GM-CSF Receptor

[0087] Example 3 is repeated with the difference that a monoclonal antibody specific for the GM-CSF receptor is used instead of a monoclonal antibody specific for the GM-CSF.

[0088] As GM-CSF antagonist, a GM-CSF receptor specific antibody comprising an amino acid sequence of a H-CDR3 sequence depicted in any one of SEQ ID No's.:27-45 is used. Another species than mouse may be used, in particular a species to which the antibody used in this experiment is cross reactive. Preferably the animal species used in this experiment is rat.

[0089] The animals, e.g. rat, treated with the isotype control antibody show significant increased signs of osteoarthritis as compared to the animals which received a GM-CSF receptor specific antibody according to the present example. This demonstrates the effectiveness of the antibodies in the treatment of OA.

Example 9

Clinical Trial

[0090] A clinical trial is performed in adult patients suffering from osteoarthritis of the knee The objective of the randomized, double-blind, placebo-controlled clinical trial is to determine the comparative differences between the GM-CSF antagonists of the present invention and placebo in overall pain relief and quality of life in a total sample of 30 patients with diagnosed osteoarthritis (OA) of the knee. Another objective is to determine the safety and tolerability of the GM-CSF antagonists of the present invention as determined by the adverse events, physical examination and vital signs.

Methods:

[0091] Thirty patients (about 15 adult males and 15 adult females), aged 40 and over, with a clinical diagnosis of osteoarthritis of the knee(s) and verified knee pain for at least 15 days in the month prior to testing are enrolled in the study. Patients receive a therapeutically effective amount of GM-CSF antagonists or a placebo (e.g. once every two weeks for about six months).

[0092] The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; Bellamy et al, J Rheumatol 15(12):1833-40, 1988) and the SF-36v2 Quality of Life instrument scales (Quality Metric Health Outcomes Solutions, Lincoln, RI) are used in the study. The WOMAC is a disease-specific, self-administered, health status measure. It probes clinically-important symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The index consists of 24 questions (5-pain, 2-stiffness and 17-physical function) and can be completed in less than 5 minutes. The WOMAC is a valid, reliable and sensitive instrument for the detection of clinically important changes in health status following a variety of interventions (pharmacologic, nutritional, surgical, physiotherapy, etc.). The WOMAC questionnaire is valid for assessing the effects of intervention on hip or knee osteoarthritis. The SF-36v2 Quality of Life instrument is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index. It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group. Accordingly, the SF-36v2 has proven useful in surveys of general and specific populations, comparing the relative burden of diseases, and in differentiating the health benefits produced by a wide range of different treatments. The SF-36v2 yields information on the following aspects and subsets of health; Physical Health (comprised of physical functioning, role-physical, bodily pain and general health) and Mental Health (comprised of vitality, social functioning, role-emotional and mental health).

Results:

[0093] Change in bodily pain: The improvement in SF-36v2 bodily pain is statistically significant in patients treated with the GM-CSF antagonists of the present invention as compared with placebo. A higher score is better because it means the patient feels less pain after taking the product. There is a statistical significant improvement in the bodily-pain score in the group that received the GM-CSF antagonists of the present invention versus the placebo group.

[0094] Change in role-physical score: The superior effect of the GM-CSF antagonists of the present invention compared with the placebo is statistically significant in week 8, week 12, and week 20 in terms of role limitations due to physical health (role physical). A higher score is better because it means that the patient noticed a physical improvement and a reduction in the limitations suffered in activities of daily living. There is a statistical significant improvement in the role-physical score in the group that received the GM-CSF antagonists of the present invention versus the placebo group.

[0095] Change in the total WOMAC score: The total WOMAC score of the group treated with the GM-CSF antagonists of the present invention is statistical significantly better than the total WOMAC score of the placebo group (a lower score is better).

[0096] Change in WOMAC ADL: The improvement in activities of daily living (measured as a WOMAC ADL sub-score) is greater in the group treated with the GM-CSF antagonists of the present invention than in the placebo group. There is an statistically significant improvement in the WOMAC ADL score in the group treated with the GM-CSF antagonists of the present invention compared to the placebo group (a lower score is better).

Conclusions:

[0097] The clinical trial shows the efficacy of the GM-CSF antagonists of the present invention in improving the quality of life of patients with osteoarthritis of the knee. The results of the clinical trial also show the product's safety and tolerance, given that no serious adverse effects were found.

[0098] The efficacy of the GM-CSF antagonists of the present invention can also be established through studies in other species to which the GM-CSF antagonists of the present invention are cross-reactive (e.g. on horses in order to evaluate joint movement); and by using in vitro studies to determine the ability of GM-CSF antagonists of the present invention to inhibit IL-1-induced agrecan degradation, conducting the assay on condrocyte cultures.

[0099] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

[0100] Bellamy et al, J Rheumatol 15(12):1833-40, 1988

[0101] Blom et al, Arthritis Rheum 56:147-157, 2007

[0102] Chose et al, J Combin Chem: 1:55-68, 1999

[0103] Knappik et al, J. Mol. Biol. 296:57, 2000

[0104] Krebs et al, J. Immunol. Methods. 254:67, 2001

[0105] Lipinski et al, Adv Drug Del Rev 23:3-25, 1997

[0106] Mills et al, J Immunol 164:6166-6173, 2000

[0107] Pritzker et al, Osteoarthritis Cartilage 14:13-29, 2006

[0108] Rothe et al, J. Mol. Biol. 376:1182, 2008

Sequence CWU 1

1

461140PRTartificialamino acid sequence of heavy chain variable region 1Met Glu Leu Ile Met Leu Phe Leu Leu Ser Gly Thr Ala Gly Val His1 5 10 15Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly 20 25 30Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp 35 40 45Tyr Asn Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Asp Trp 50 55 60Ile Gly Tyr Ile Ala Pro Tyr Ser Gly Gly Thr Gly Tyr Asn Gln Glu65 70 75 80Phe Lys Asn Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala 85 90 95Tyr Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr 100 105 110Cys Ala Arg Arg Asp Arg Phe Pro Tyr Tyr Phe Asp Tyr Trp Gly Gln 115 120 125Gly Thr Thr Leu Arg Val Ser Ser Val Ser Gly Ser 130 135 1402150PRTartificialamino acid sequence of light chain variable region 2Met Gly Phe Lys Met Glu Ser Gln Ile Gln Val Phe Val Tyr Met Leu1 5 10 15Leu Trp Leu Ser Gly Val Asp Gly Asp Ile Val Met Ile Gln Ser Gln 20 25 30Lys Phe Val Ser Thr Ser Val Gly Asp Arg Val Asn Ile Thr Cys Lys 35 40 45Ala Ser Gln Asn Val Gly Ser Asn Val Ala Trp Leu Gln Gln Lys Pro 50 55 60Gly Gln Ser Pro Lys Thr Leu Ile Tyr Ser Ala Ser Tyr Arg Ser Gly65 70 75 80Arg Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Ile 85 90 95Leu Thr Ile Thr Thr Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys 100 105 110Gln Gln Phe Asn Arg Ser Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu 115 120 125Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro 130 135 140Ser Ser Lys Gly Glu Phe145 1503117PRTartificialamino acid sequence of heavy chain variable region 3Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile Glu Asn Lys Tyr Ala Gly Gly Ala Thr Tyr Tyr Ala Ala 50 55 60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr65 70 75 80Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95Tyr Cys Ala Arg Gly Phe Gly Thr Asp Phe Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ser 1154105PRTartificialamino acid sequence of light chain variable region 4Asp Ile Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln1 5 10 15Thr Ala Arg Ile Ser Cys Ser Gly Asp Ser Ile Gly Lys Lys Tyr Ala 20 25 30Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45Lys Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser 50 55 60Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Glu Asp Glu65 70 75 80Ala Asp Tyr Tyr Cys Ser Ala Trp Gly Lys Gly Met Val Phe Gly Gly 85 90 95Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105510PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 5Ser Gly Leu Ile Phe Asp Tyr Trp Leu Asp1 5 10610PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 6Ser Gly Leu Ile Ile Asp Ala Leu Ser Pro1 5 10710PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 7Thr Ser Leu Met Ser Ile Tyr Phe Asp Tyr1 5 10810PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 8Ser Gly Leu Leu Phe Leu Tyr Phe Asp Tyr1 5 10910PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 9Ser Gly Leu Ile Asn Leu Gly Met His Pro1 5 101010PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 10Ser Gly Leu Ile Phe Asp Ala Leu Arg Asp1 5 101110PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 11Ser Gly Leu Ile Phe Asp Lys Leu Thr Ser1 5 101210PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 12Ser Gly Leu Ile Asn Leu His Phe Asp Thr1 5 101310PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 13Ser Thr His Phe Ser Ala Tyr Phe Asp Tyr1 5 101410PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 14Ser Gly Leu Ile Met Asp Lys Leu Asp Asn1 5 101510PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 15Ser Gly Leu Ile Ile Asp Asn Leu Asn Pro1 5 101610PRTartificialamino acid sequence of Homo sapiens CDR3 (H-CDR3) 16Ser Gly Leu Ile Ala Val Tyr Phe Asp Tyr1 5 10175PRTartificialamino acid sequence of heavy CDR1 (H-CDR1) 17Asp Tyr Leu Leu His1 51817PRTartificialamino acid sequence of heavy CDR2 (H-CDR2) 18Trp Leu Asn Pro Tyr Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe Gln1 5 10 15Gly1911PRTartificialamino acid sequence of light CDR1 (L-CDR1) 19Arg Ala Ser Gln Asn Ile Arg Asn Ile Leu Asn1 5 10207PRTartificialamino acid sequence of light CDR2 (L-CDR2) 20Ala Ala Ser Asn Leu Gln Ser1 5219PRTartificialamino acid sequence of light CDR3 (L-CDR3) 21Gln Gln Ser Tyr Ser Met Pro Arg Thr1 52212PRTartificialamino acid sequence of light CDR1 (L-CDR1) 22Arg Ala Ser His Arg Val Ser Ser Asn Tyr Leu Ala1 5 10237PRTartificialamino acid sequence of light CDR2 (L-CDR2) 23Gly Ala Ser Asn Arg Ala Thr1 5249PRTartificialamino acid sequence of light CDR3 (L-CDR3) 24Gln Gln Tyr Ala Ser Ser Pro Val Thr1 52510PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 25Gly Tyr Ile Phe Pro Thr Phe Ala Leu His1 5 102616PRTartificialamino acid sequence of heavy CDR2 (H-CDR2) 26Ser Ile Asn Thr Ala Ser Gly Lys Thr Lys Phe Ser Thr Lys Phe Gln1 5 10 152713PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 27Asp Arg Phe Gln Asn Ile Met Ala Thr Ile Leu Asp Val1 5 102811PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 28Val Gly Ser Phe Ser Gly Ile Ala Tyr Arg Pro1 5 102911PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 29Val Gly Ser Phe Ser Gly Pro Ala Leu Arg Pro1 5 103011PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 30Val Gly Ser Phe Ser Pro Pro Thr Tyr Gly Tyr1 5 103111PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 31Val Gly Ser Phe Ser Gly Tyr Pro Tyr Arg Pro1 5 103211PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 32Val Gly Ser Phe Ser Pro Leu Thr Leu Gly Leu1 5 103311PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 33Val Gly Ser Phe Ser Gly Pro Val Tyr Gly Leu1 5 103411PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 34Val Gly Ser Phe Ser Pro Pro Ala Tyr Arg Pro1 5 103511PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 35Val Gly Ser Phe Ser Pro Val Thr Tyr Gly Leu1 5 103611PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 36Val Gly Ser Phe Ser Gly Leu Ala Tyr Arg Pro1 5 103711PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 37Val Gly Ser Phe Ser Pro Ile Thr Tyr Gly Leu1 5 103811PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 38Val Gly Ser Phe Ser Gly Trp Ala Phe Asp Tyr1 5 103911PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 39Val Gly Ser Phe Ser Gly Trp Ala Phe Asp Tyr1 5 104011PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 40Leu Gly Ser Val Thr Ala Trp Ala Phe Asp Tyr1 5 104111PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 41Ala Gly Ser Ile Pro Gly Trp Ala Phe Asp Tyr1 5 104211PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 42Val Gly Ser Phe Ser Pro Leu Thr Met Gly Leu1 5 104311PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 43Val Gly Ser Phe Ser Pro Leu Thr Met Gly Leu1 5 104411PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 44Val Gly Ser Phe Ser Gly Pro Ala Leu His Leu1 5 104511PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 45Val Gly Ser Val Ser Arg Ile Thr Tyr Gly Phe1 5 104611PRTartificialamino acid sequence of heavy CDR3 (H-CDR3) 46Val Gly Ser Phe Ser Pro Leu Thr Leu Gly Leu1 5 10

Claims

1. A method for decreasing or preventing cartilage damage, osteophyte formation and joint deformation in a human subject with osteoarthritis, comprising the step of administering to the subject an effective amount of an antibody specific for GM-CSF or the GM-CSF Receptor.

2. The method according to claim 1, wherein the antibody comprises the heavy chain variable region amino acid sequence of SEQ ID NO: 3, or the light chain variable region amino acid sequence of SEQ ID NO: 4.

3. The method according to claim 1, wherein the antibody comprises a H-CDR3 sequence selected from any one of SEQ ID NOs: 5-16, a H-CDR1 sequence of SEQ ID NO: 17, a H-CDR2 sequence of SEQ ID NO: 18, a L-CDR1 sequence of SEQ ID NO: 19, a L-CDR2 sequence of SEQ ID NO: 20 and a L-CDR3 sequence of SEQ ID NO: 21.

4. The method according to claim 1, wherein the antibody comprises a H-CDR3 sequence selected from any one of SEQ ID NOs: 28-46.